First-Line Treatment Approaches for EGFR-mutated Metastatic NSCLC: Updates from MARIPOSA High-Risk Analyses

An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and FLAURA2, and shares their impression of icPFS and DoR from MARIPOSA, along with how to determine which patients are best suited for either combination treatment option.

EP: 1.A 55-Year-Old Man with EGFR-mutated Advanced/Metastatic NSCLC

EP: 2.Recent Advances in First-Line Combination Therapy for EGFR-mutated Metastatic NSCLC: Exploring Amivantamab + Lazertinib and Osimertinib-Based Regimens

EP: 3.An Academic Perspective to Making First-Line Treatment Decisions for EGFR-mutated Metastatic NSCLC

Now Viewing

EP: 4.First-Line Treatment Approaches for EGFR-mutated Metastatic NSCLC: Updates from MARIPOSA High-Risk Analyses

EP: 5.Management of Adverse Events with First-Line Combination Therapies for EGFR-mutated NSCLC

EP: 6.Considerations for Treatment of Advanced/Metastatic EGFR-mutated NSCLC

• Please discuss a treatment approach for the patient case above.
• How do factors like brain metastases influence your 1L treatment choice?
• How do you determine which patients are best suited for either combination treatment option?

Recent Videos